CD
STML

Carl Domino’s Stemline Therapeutics, Inc. STML Stock Holding History

Carl Domino’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$289K Hold
26,000
– – 0.35% 73
2017
Q2 		$239K Hold
26,000
– – 0.28% 91
2017
Q1 		$222K Hold
26,000
– – 0.24% 96
2016
Q4 		$278K Hold
26,000
– – 0.3% 83
2016
Q3 		$267K Sell
26,000
-305
-1% -$2.48K 0.25% 95
2016
Q2 		$178K Buy
26,305
+3,000
+13% +$18.9K 0.17% 118
2016
Q1 		$109K Buy
23,305
+5,000
+27% +$24.4K 0.1% 134
2015
Q4 		$116K Buy
+18,305
New +$149K 0.09% 143
2015
Q3 		– Sell
-16,796
Closed -$198K – 154
2015
Q2 		$198K Buy
16,796
+4,000
+31% +$55.5K 0.14% 140
2015
Q1 		$185K Sell
12,796
-2,000
-14% -$30.6K 0.14% 148
2014
Q4 		$252K Sell
14,796
-7,400
-33% -$107K 0.14% 130
2014
Q3 		$277K Buy
22,196
+7,696
+53% +$94.7K 0.15% 120
2014
Q2 		$213K Buy
+14,500
New +$222K 0.11% 156
2014
Q1 		– Sell
-12,100
Closed -$237K – 173
2013
Q4 		$237K Buy
+12,100
New +$323K 0.13% 134

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carl Domino's STML Position: Q3 2017 in Review

Carl Domino held its Stemline Therapeutics, Inc. (STML) position steady in Q3 2017 at 26,000 shares worth $289K. The position accounts for 0.35% of the portfolio, ranked #73.

Carl Domino first reported a position in STML in Q4 2013 and has held it in 14 quarters since. 79 funds tracked by Wall St. Rank hold STML as of Q3 2017.

  • Carl Domino held 26,000 shares of Stemline Therapeutics, Inc. worth $289K as of Q3 2017.
  • Carl Domino left its Stemline Therapeutics, Inc. share count unchanged in Q3 2017.
  • Stemline Therapeutics, Inc. made up 0.35% of Carl Domino's portfolio in Q3 2017, its #73 holding.
  • Carl Domino first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and has held it in 14 quarters since.
  • 79 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2017.

Based on Carl Domino's 13F filing for Q3 2017, filed 7 Nov 2017.